ClinicalTrials.gg
RecruitingNCT06123091Updated Nov 8, 2023

Exploring Patient Reported Outcomes in Inherited Ichthyosis

An observational study in Congenital Ichthyosis, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Maastricht University Medical Center · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
16 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn about the presence of extracutaneous manifestations in patients with congenital ichthyosis.

The main question it aims to answer is:

  • Do patients with congenital ichthyosis experience extracutaneous manifestations?

Participants will fill in questionnaires in which the investigators will explore whether patients experience extracutaneous manifestations, and if so what these manifestations entail. Examples of such questions are whether patients experience (joint) pain or whether they experience hindrance due to their complaints.

Read the detailed description

There is only limited knowledge about extracutaneous manifestations in patients with congenital ichthyosis. With this study, the investigators aim to identify extracutaneous manifestations with questionaires based on patient reported outcomes.

Secondary research questions include:

  • What is the prevalence of joint complaints in patients with congenital ichthyosis
  • What is the influence of ichthyosis on the quality of life patients experience

Furthermore, the investigators aim to discover knowledge gaps in current patient management and possible areas of improvement in patient care towards healthcare professionals.

02

Conditions studied

  • Congenital Ichthyosis
03

In context

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients 16 years and older, who have a clinically and genetically confirmed congenital ichthyosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 years and older
  • Clinically and genetically confirmed congenital ichthyosis

Exclusion criteria

Exclusion Criteria:

  • \<16 years of age
  • Not able to read Dutch
  • Not able to fill in questionnaires online or in print
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Congenital ichthyosis patients

    Questionnaires

    Other: Questionnaires with patient reported outcome measures

Interventions

  • OtherQuestionnaires with patient reported outcome measures

    Questionnaires to gain insight of the prevalence of extracutaneous manifestations and the impact of the disease on the quality of life.

06

What researchers measure

Primary outcomes

  1. Extracutaneous manifestations in general

    Evaluation of possible extracutaneous manifestations patients with congenital ichthyosis exhibit. This is measured by a questionnaire the investigators have composed. The questions entail patient reported outcomes on their general health and the health issues patients experience due to ichthyosis.

    Time frame: Day 1

Secondary outcomes

  1. Prevalence of joint complaints measured by the Psoriasis Epidemiology Screening Tool

    Prevalence of joint complaints measured by the Psoriasis Epidemiology Screening Tool (PEST). The higher the total score, the more joint complaints patients with congenital ichthyosis experience.

    Time frame: Day 1

  2. Prevalence of joint complaints measured by the Early Arthritis Recognition Clinic questionnaire

    Prevalence of joint complaints measured by the Early Arthritis Recognition Clinic (EARC) questionnaire. The higher the total score, the more joint complaints patients with congenital ichthyosis experience.

    Time frame: Day 1

  3. Prevalence of joint complaints Early Arthritis for Psoriatic patients questionnaire

    Prevalence of joint complaints measured by the Early Arthritis for Psoriatic patients (EARP) questionnaire. The higher the total score, the more joint complaints patients with congenital ichthyosis experience.

    Time frame: Day 1

  4. Prevalence of joint complaints measured by the Clinical Arthritis Rule questionnaire

    Prevalence of joint complaints measured by the Clinical Arthritis Rule (CARE) questionnaire. The higher the total score, the more joint complaints patients with congenital ichthyosis experience.

    Time frame: Day 1

  5. Impact of ichthyosis on quality of life

    Evaluation of quality of life measured by the Dermatology Life Quality Index (DLQI) questionnaire. Scores range from 0-30, where a higher score indicates that the skin disease has a bigger influence on their quality of life.

    Time frame: Day 1

  6. Impact of ichthyosis on quality of life measured by Skindex-29

    Evaluation of the quality of life of patients with congenital ichthyosis measured by the Skindex-29 questionnaire. Scores ranging from \>25 and \>44, where a higher score indicates that the skin disease has a bigger influence on their quality of life.

    Time frame: Day 1

  7. Prevalence of itch complaints

    Evaluation of possible extracutaneous manifestations patients with congenital ichthyosis exhibit. This is measured by a numeric rating scale (NRS) of itch. The higher the outcome, the more itch patients experience

    Time frame: Day 1

  8. Prevalence of pain complaints

    Evaluation of possible extracutaneous manifestations patients with congenital ichthyosis exhibit. This is measured by a numeric rating scale (NRS) of pain. The higher the outcome, the more pain the patients experience

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Oct 2024, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Nov 8, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Oct 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06123091
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Sep 1, 2023
Primary completion
Oct 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Nov 8, 2023

Study contacts

Vanya Rossel, MD
Contact
vanya.rossel@mumc.nl
+31(0)43-3877295
Antoni C Gostynski, MD, PhD
principal investigator · Maastricht UMC+

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion